EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Comparison of In Vitro Activity of Ceftazidime-Avibactam and Imipenem-Relebactam against Clinical Isolates of Pseudomonas aeruginosa

Leilei Wang, Xuefei Zhang, Xun Zhou, Fan Yang iD, Qinglan Guo iD, Minggui Wang iD

Microbiology Spectrum · 15.06.2023 · 11 (3)

DOI: 10.1128/spectrum.00932-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, erschienen am 15.06.2023. Verfasst von Leilei Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Ceftazidime, Pseudomonas Infections. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Municipal Science and Technology Commission, MOST | National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The emergence of antimicrobial resistance poses a particular challenge globally, and the concept of P. aeruginosa with “difficult-to-treat” resistance (DTR- P. aeruginosa ) was proposed. Here, P. aeruginosa clinical isolates were highly susceptible to three β-lactamase inhibitor combinations, CZA, IMR, and ceftolozane-tazobactam.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CeftazidimePseudomonas InfectionsHumansPseudomonas aeruginosabeta-Lactamase InhibitorsAnti-Bacterial AgentsCephalosporinsTazobactambeta-LactamasesImipenemMicrobial Sensitivity TestsDrug CombinationsAzabicyclo Compounds

Stichwörter der Autor:innen

Pseudomonas aeruginosaceftazidime-avibactamimipenem-relebactamin vitro activity

Substanzen

Ceftazidimebeta-Lactamase InhibitorsAnti-Bacterial AgentsCephalosporinsTazobactambeta-LactamasesImipenemavibactam, ceftazidime drug combinationDrug CombinationsAzabicyclo Compounds

Autor:innen und Institutionen

  • Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
  • Key Laboratory of Clinical Pharmacology of Antibiotics, National Heath Commission of People's Republic of China, Shanghai, China.

ORCID-Profile: Fan Yang, Qinglan Guo, Minggui Wang

Förderung

  • Shanghai Municipal Science and Technology Commission
  • MOST | National Natural Science Foundation of China

Zitieren

APA

Wang, L., Zhang, X., Zhou, X., Yang, F., Guo, Q., & Wang, M. (2023). Comparison of In Vitro Activity of Ceftazidime-Avibactam and Imipenem-Relebactam against Clinical Isolates of Pseudomonas aeruginosa. Microbiology Spectrum, 11(3). https://doi.org/10.1128/spectrum.00932-23

Vancouver

Wang L, Zhang X, Zhou X, Yang F, Guo Q, Wang M. Comparison of In Vitro Activity of Ceftazidime-Avibactam and Imipenem-Relebactam against Clinical Isolates of Pseudomonas aeruginosa. Microbiology Spectrum. 2023;11(3). doi:10.1128/spectrum.00932-23

BibTeX
@article{Wang2023,
  author = {Wang, Leilei and Zhang, Xuefei and Zhou, Xun and Yang, Fan and Guo, Qinglan and Wang, Minggui},
  title = {Comparison of In Vitro Activity of Ceftazidime-Avibactam and Imipenem-Relebactam against Clinical Isolates of Pseudomonas aeruginosa},
  journal = {Microbiology Spectrum},
  year = {2023},
  volume = {11},
  number = {3},
  doi = {10.1128/spectrum.00932-23}
}
Kostenlos starten →